AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Axsome Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$155.81−1.33 (-0.85%)
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
92.6%
Operating margin
-26.1%
Net margin
-28.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +65.5% | +133.7% | – | – | |
| Gross profit | +67.7% | +136.2% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -80.0% | -70.4% | -252.1% | |
| Return on assets | -62.3% | -50.6% | -29.1% | |
| Current ratio | 5.30 | 7.85 | 1.55 | |
| Debt to equity | 0.45 | 0.42 | 2.13 | |
| Interest coverage | – | – | 10.5× | |
| Inventory turnover | – | – | 2.2× | |
| Capex to revenue | – | – | 0.1% | |
| Diluted shares | 19M | 37M | 50M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Axsome Therapeutics generated $591.63M from operations and spent $2.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$591.63M
Used
$2.34M
Capital expenditure$2.34M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-28.7%
×Asset turnover1.01×
×Equity multiplier8.66×
=Return on equity, FY2025-252.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -28.7% | 1.01× | 8.66× | -252.1% |
| FY2024 | -74.5% | 0.67× | 4.66× | -231.6% |
| FY2023 | -88.4% | 0.59× | 3.06× | -159.2% |
| FY2022 | -374.0% | 0.24× | 3.35× | -299.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$183.17M
- Cash generatingOperating cash flow above zero-$93.41M
- Return on assets improvedROA up on the prior year-48.8% → -32.2%
- Earnings backed by cashOperating cash flow above net income-$93.41M vs -$183.17M
- Less leverageLong-term debt to assets fell31.8% → 17.1%
- Better liquidityCurrent ratio rose2.11 → 1.55
- No dilutionShare count did not rise48M → 50M
- Gross margin improvedGross margin up on the prior year91.37% → 92.56%
- More efficientAsset turnover rose0.66 → 1.12